Thérapies ciblées dans le carcinome hépatocellulaire

Bosch, 2004, Primary liver cancer: worldwide incidence and trends, Gastroenterology, 127, S5, 10.1053/j.gastro.2004.09.011 Chevret, 1999, A new prognostic classification for predicting survival in patients with hepatocellular carcinoma, J Hepatol, 31, 133, 10.1016/S0168-8278(99)80173-1 Bruix, 2006, New aspects of diagnosis and therapy of hepatocellular carcinoma, Oncogene, 25, 3848, 10.1038/sj.onc.1209548 Llovet, 2008, Design and endpoints of clinical trials in hepatocellular carcinoma, J Natl Cancer Inst, 100, 698, 10.1093/jnci/djn134 Ribatti, 2006, Angiogenesis and anti-angiogenesis in hepatocellular carcinoma, Cancer Treat Rev, 32, 437, 10.1016/j.ctrv.2006.06.002 Poon, 2002, Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study, J Clin Oncol, 20, 1775, 10.1200/JCO.2002.07.089 Mann, 2007, Pronostic molecular markers in hepatocellular carcinoma: a systematic review, Eur J Cancer, 43, 979, 10.1016/j.ejca.2007.01.004 Liu, 2005, Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584, Cancer Res, 65, 3691, 10.1158/0008-5472.CAN-04-3462 Yau, 2009, Management of advanced hepatocellular carcinoma in the era of targeted therapy, Liver Int, 29, 10, 10.1111/j.1478-3231.2008.01916.x Malka, 2007, Bevacizumab in patients with advanced hepatocellular carcinoma (HCC): preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring, J Clin Oncol, 25, 4570, 10.1200/jco.2007.25.18_suppl.4570 Siegel, 2008, Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma, J Clin Oncol, 26, 2992, 10.1200/JCO.2007.15.9947 Abou-Alfa, 2006, Phase II study of sorafenib in patients with advanced hepatocellular carcinoma, J Clin Oncol, 24, 4293, 10.1200/JCO.2005.01.3441 Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857 Cheng, 2009, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, 10, 25, 10.1016/S1470-2045(08)70285-7 Llovet, 2009, Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): collective results from the phase III sorafenib HCC assessment randomized protocol (SHARP) and Asia-Pacific (AP) trials, The European CanCer Organisation ECCO 15 and European Society for Medical Oncology ESMO, 34, 367 Faivre, 2006, Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer, J Clin Oncol, 24, 25, 10.1200/JCO.2005.02.2194 Faivre, 2009, Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study, Lancet Oncol, 10, 794, 10.1016/S1470-2045(09)70171-8 Zhu, 2009, Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study, J Clin Oncol, 27, 3027, 10.1200/JCO.2008.20.9908 Koeberle, 2009, Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma (HCC): A multicenter phase II trial (SAKK 77/06 and SASL 23), J Clin Oncol, 27, 4591, 10.1200/jco.2009.27.15_suppl.4591 Rizell, 2008, Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer, Int J Clin Oncol, 13, 66, 10.1007/s10147-007-0733-3 Decaens, 2008, Pilot study of sirolimus in cirrhotic patients with advanced hepatocellular carcinoma, J Hepatol, 48, S13, 10.1016/S0168-8278(08)60030-6 Gruenwald, 2007, A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma – final results, J Clin Oncol, 25, 4598, 10.1200/jco.2007.25.18_suppl.4598 Philip, 2005, Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer, J Clin Oncol, 23, 6657, 10.1200/JCO.2005.14.696 Desbois-Mouthon, 2006, Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib, Int J Cancer, 119, 2557, 10.1002/ijc.22221 Teicher, 1996, A systems approach to cancer therapy (Antioncogenics+standard cytotoxics-->mechanism(s) of interaction), Cancer Metastasis Rev, 15, 247, 10.1007/BF00437479 Le Tourneau, 2008, Association chimiothérapie, thérapie ciblée. Thérapeutiques antiangiogéniques en cancérologie Zhu, 2006, Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma, J Clin Oncol, 24, 1898, 10.1200/JCO.2005.04.9130 Sun, 2007, Combination of capecitabine and oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma: a phase II study, J Clin Oncol, 25, 4574, 10.1200/jco.2007.25.18_suppl.4574 Hsu, 2008, Phase II study of bevacizumab plus capecitabine in patients with advanced/metastatic hepatocellular carcinoma: final report, J Clin Oncol, 26, 4603, 10.1200/jco.2008.26.15_suppl.4603 Asnacios, 2008, Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma (HCC): results of a multicenter phase II study, Cancer, 112, 2733, 10.1002/cncr.23489 O’Neil, 2008, Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma, J Clin Oncol, 26, 4604, 10.1200/jco.2008.26.15_suppl.4604 Abou-Alfa, 2008, Final results from a phase II (PhII), randomized, double-blind study of sorafenib plus doxorubicin (S+D) versus placebo plus doxorubicin (P+D) in patients (pts) with advanced hepatocellular carcinoma (AHCC), American Society of Clinical Oncology Gastrointestinal Cancers Symposium, 132 Calvisi, 2006, Ubiquitous activation of Ras and Jak/Stat pathways in human HCC, Gastroenterology, 130, 1117, 10.1053/j.gastro.2006.01.006 Azad, 2008, Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity, J Clin Oncol, 26, 3709, 10.1200/JCO.2007.10.8332 Thomas, 2009, Phase II Trial of the Combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma, J Clin Oncol, 27, 843, 10.1200/JCO.2008.18.3301 Wang, 2008, Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma, Clin Cancer Res, 15, 5124, 10.1158/1078-0432.CCR-07-4774 Huynh, 2008, Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma, J Hepatol, 49, 52, 10.1016/j.jhep.2008.02.022 Zhou, 2009, A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma, Ann Surg, 249, 195, 10.1097/SLA.0b013e3181961c16 Shiina, 2005, A randomized control trails of radiofréquency ablation with ethanol injection for small hepatocellular carcinoma, Gastroenterology, 129, 122, 10.1053/j.gastro.2005.04.009 Imamura, 2003, Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy, J Hepatol, 38, 200, 10.1016/S0168-8278(02)00360-4 Llovet, 2008, Novel advancement in the management of hepatocellular carcinoma in 2008, J Hepatol, 48, S20, 10.1016/j.jhep.2008.01.022 Schwartz, 2002, Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials, Lancet Oncol, 3, 593, 10.1016/S1470-2045(02)00873-2 Hakimé, 2007, Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice, Radiology, 244, 464, 10.1148/radiol.2442061005 Sergio, 2008, Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness, Am J Gastroenterol, 103, 914, 10.1111/j.1572-0241.2007.01712.x Xiao, 2009, Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells, World J Gastroenterol, 15, 4582, 10.3748/wjg.15.4582 Faivre, 2008, Evaluation de la réponse tumorale biomarqueurs et perspectives. Thérapeutiques antiangiogéniques en cancérologie Choi, 2007, Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria, J Clin Oncol, 25, 1753, 10.1200/JCO.2006.07.3049 Su, 2005, Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma, Cancer Lett, 224, 117, 10.1016/j.canlet.2004.10.010 Judde, 2007, Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response, Int J Cancer, 120, 1579, 10.1002/ijc.22364 Faivre, 2009, Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity endpoints, J Clin Oncol, 27, e248, 10.1200/JCO.2009.25.0670 M. Bouattour, C. Dreyer, S. Faivre, E. Raymond. New antiangiogenic compounds and strategies for their clinical development. In : Hernán Cortés-Funes editor. International Oncology Updates. Present and future for antiangiogenic therapies in cancer. 1st ed. Barcelona: Permnayer Publications; 2010. (sous presse). Kelley, 2008, Sorafenib in hepatocellular carcinoma: separating the hype from the hope, J Clin Oncol, 26, 5845, 10.1200/JCO.2008.19.7996